Beam Therapeutics is pioneering the use of proprietary base-editing technology to develop powerful, uniquely precise genetic machines that rewrite genetic code, one letter at a time.
Cambridge, Mass. – Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced that it has been named by FierceBiotech…
Read MoreBase editing technology builds on CRISPR to enable single-letter editing of DNA and RNA Co-founded by scientific pioneers David R. Liu, Feng Zhang, and…
Read MoreDrugs based on gene editing are still in the earliest stages of development, but that’s not stopping new players looking at refining and improving…
Read MoreMost genetic diseases in humans are caused by point mutations—single base errors in the DNA sequence.
Read MoreSince its discovery in 2012 CRISPR-Cas9, a gene-editing technique, has gone from strength to strength. This tool, developed from a bacterial defense system that…
Read MoreGenetics is having a moment in the sun. Last year, biologists at the University of Bath in England created mice with neon feet.
Read More
The foundation of Beam’s work to develop precision genetic medicines is groundbreaking research coming out of the laboratories of our founders. Our base editing technologies were the subject of research published in Nature and Science in 2016 and 2017.